Connect with us

Health

Pharmacyte Biotech Inc (OTCMKTS:PMCB) Entrusts Austrianova With The Encapsulation Of Clinical Trial Cells

Published

on

Pharmacyte Biotech Inc (OTCMKTS:PMCB) has moved ahead to disclose that the vials of cells from PharmaCyte’s Master Cell Bank (MCB) have already been moved to the Austrianova’s encapsulation facility situated in Thailand and that was done by Eurofins Lancaster Laboratories (Eurofins).

A person well conversant with the matter has revealed that the cells from the MCB will be encapsulated and what will follow will be a series of tests that will be conducted by Austrianova. He said that the company would be looking forward to see the post-encapsulation tests generate what was remaining in terms of data so that the U.S. Food and Drug Administration (FDA) could move fast in accomplishing its role. The body insists that it must be included in the New Drug Application (IND).

The target is to do all that it takes to ensu5re that the cells are eventually shipped and the accepted into Austrianova’s GMP encapsulation facility, a matter that will require that it makes it through the mandatory mycoplasma and sterility testing by Eurofins.

Kenneth L. Waggoner, who happens to be PharmaCyte’s Chief Executive Officer while walking out of a business conference that was held recently came across several journalists who wanted to get his perspective regarding the latest developments.

He said that as a Company they were quite pleased to be making the announcement at the moment. According to him, it was a significant step forward in line with the making preparations for the company’s planned clinical trial targeted at dealing with the locally advanced, non-metastatic, inoperable pancreatic cancer (LAPC).

The official outlined that after encapsulation they would be moving forward to push for more tests to be conducted, a matter they would be entrusting with Austrianova. Fundamentally, the data that will be emanating from the tests as well as from that coming from tests conducted by Eurofins and its subcontractors will b merged and then included to form part of an integral part of the company’s IND.

Brian Salmons, who happens to be Austrianova’s Chief Executive Officer in making his latest statement, revealed that they were excited to receive vials of cells produced by Eurofins making their way in from MCB.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.